ARISTOTLE study data should be available at the European Society of Cardiology Aug. 2011. ADOPT study is scheduled to be completed in May 2011 so data are not far away either. Bleeding risk could be better than Xarelto given lower peak blood levels and BID dosing limiting the peak-to-trough ratio.
Market Data 
Markets 
AI
